Considering the second rank of the KRAS G12V mutation in all KRAS-mutated cancers (24%) and high prevalence of HLA-A*11:01 in Chinese and Asian populations of the United States (both >30%) (13), our HLA-A*11:01–restricted mutant KRAS G12V8–16–reactive TCR could be used in TCR-based therapies for a large number of patients with KRAS-mutated cancer within these 2 populations (>7.2%). Here, KRAS is linked to cancer.